OBJECTIVE: To examine the effect of @entity7786 and the timing of pubertal induction on final height in @entity1 with @entity2689 receiving a standard dose of @entity2124 . DESIGN: Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. @entity1 : @entity1 with @entity2689 aged 7-13 years at recruitment, receiving recombinant @entity2124 therapy (10 mg/m(2)/week). INTERVENTIONS: @entity1 were randomised to @entity7786 (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of @entity2670 at 12 years were further randomised to oral @entity2082 (year 1, 2   g daily; year 2, 4  g daily; year 3, 4 months each of 6, 8, and 10  g daily) or placebo; @entity1 who received placebo and those recruited after the age of 12.25 years started @entity2082 at age 14. MAIN OUTCOME MEASURE: Final height. Results 106 @entity1 were recruited, of whom 14 withdrew and 82/92 reached final height. Both @entity7786 and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P = 0.001, n = 82) for @entity7786 and 3.8 (0.0 to 7.5) cm (P = 0.05, n = 48) for late pubertal induction with @entity2082 . In the 48 @entity1 who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of @entity7786 alone, late induction alone, and @entity7786 plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P < 0.001). No cases of virilisation were reported. CONCLUSION: @entity7786 had a positive effect on final height in @entity1 with @entity2689 treated with @entity2124 , as did late pubertal induction with @entity2082 at age 14 years. However, these effects were not additive, so using both had no advantage. @entity7786 could, therefore, be offered as an alternative to late pubertal induction for increasing final height in @entity2689 . Trial registration Current Controlled Trials ISRCTN50343149.

Effect of @entity7786 and timing of pubertal induction on final height in XXXX : randomised, double blind, placebo controlled trial.

@entity1 :: ('9606', 'Species') :: ['participants', 'children', 'Participants', 'girls', 'PARTICIPANTS', 'Girls'] @entity2082 :: ('MESH:D004997', 'Chemical') :: ['ethinylestradiol'] @entity2124 :: ('2688', 'Gene') :: ['growth hormone'] @entity7786 :: ('MESH:D010074', 'Chemical') :: ['Oxandrolone', 'oxandrolone'] @entity2689 :: ('MESH:D014424', 'Disease') :: ["Turner's syndrome"] @entity2670 :: ('MESH:D010049', 'Disease') :: ['ovarian failure']
@entity2689 :: (MESH:D014424,Disease) :: ['Turner's syndrome']
